Overall, the data indicate that treatment with SCoV2-epitope leads to an increase in the secretion of proinflammatory cytokine GM-CSF while decreasing the secretion of TNF-α, IL-6, and CCL2, which can contribute to the damage of primary cardiomyocytes and potentially lead to cardiac failure. Here, CSF2 is linked to heart failure.